
Paige was a Pathology AI company founded in 2017 and based in New York, United States. It was acquired by Tempus AI in 2025 for $81.3M.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Aug 22, 2025 | Acquired | $81.3M | — | Tempus AI |
| Mar 9, 2021 | Series C | $25M | — | KKR |
| Jan 14, 2021 |
| Series C |
| $100M |
| — |
| Casdin Capital, Johnson & Johnson Innovation – JJDC |
| Jul 13, 2020 | Series B | $20M | — | Goldman Sachs, Healthcare Venture Partners |
| Dec 18, 2019 | Series B | $45M | — | Healthcare Venture Partners |
| Feb 5, 2018 | Series A | $25M | — | Breyer Capital |
No articles ingested yet for Paige. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
An AI-powered diagnostic suite that aids pathologists in detecting and grading prostate cancer on H&E-stained whole-slide images of prostate needle biopsies. Paige Prostate Detect was the first AI-based pathology software to receive FDA approval for assisting in the primary diagnosis of prostate cancer. The suite improves diagnostic accuracy across experience levels by automatically analyzing slides and flagging suspicious regions for pathologist review.
A set of AI applications designed to support pathologists in the identification and classification of breast cancer on H&E-stained whole-slide images from breast biopsy and excision specimens. The suite helps pathologists detect suspicious lesions and classify cancer subtypes, improving workflow efficiency and diagnostic confidence in breast pathology.
A portfolio of AI-powered applications that support pathologists in the detection and classification of cancers in gastrointestinal tissue samples. The suite brings Paige's proven AI technology to GI pathology, helping pathologists identify suspicious regions and reduce diagnostic turnaround times.
An FDA-cleared whole-slide image viewer that enables pathologists to view, manage, and share digital slides of tissue samples for primary diagnosis. FullFocus is vendor-neutral and integrates with various scanners and LIS applications, providing robust diagnostic tools, AI visualization overlays, and collaboration features that unlock digital pathology's full potential in clinical workflows.
A large foundation model for pathology trained on over 2.3 million whole-slide images spanning hundreds of thousands of patient cases. Virchow is available under an open-source license and provides a powerful base for developing AI applications across multiple cancer types. It enables researchers and developers to build upon Paige's extensive pathology dataset for novel diagnostic tools and biomarker discovery.

We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗